Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Drugmaker Eli Lilly & Company today announced the FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory...
The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a...
The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study...
The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's...
The Alzheimer's Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) announced today a new Precision Prevention...
The Alzheimer's Drug Discovery Foundation (ADDF) has presented Rhoda Au, PhD, MBA, Professor of Anatomy and Neurobiology at the Boston University...
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported by Eli Lilly and Company today for its anti-amyloid...
Today's FDA approval of the monoclonal antibody lecanemab (Leqembi) for the treatment of patients with mild cognitive impairment or early stage...
Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that lecanemab (leqembi) showed clinical benefit in...
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their...
The Alzheimer's Drug Discovery Foundation (ADDF) today announced that Leonard A. Lauder and Ronald S. Lauder, along with the entire third generation...
The Alzheimer's Drug Discovery Foundation will host a symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" at...
Drugmaker Eli Lilly & Co announced today that the FDA has issued a complete response letter, meaning it has not granted accelerated approval for...
Today's FDA approval of the monoclonal antibody lecanemab (Leqembi) for the treatment of patients with early Alzheimer's disease and confirmed...
The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why...
Based on study results presented today at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference and published in The New England Journal...
The Alzheimer's Drug Discovery Foundation will be moderating a session, "Beyond Amyloid and Tau: Emerging Solutions," at the 2022 Clinical Trials on...
The Alzheimer's Drug Discovery Foundation (ADDF) remains incredibly enthusiastic about the current state of drug development for Alzheimer's despite...
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eisai and Biogen for their amyloid-clearing ...
The Alzheimer's Drug Discovery Foundation (ADDF) has named Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake ...
Target ALS and the Alzheimer's Drug Discovery Foundation (ADDF) announced today the first four award recipients in a new initiative to identify and...
Alzheimer's Drug Discovery Foundation launches second phase of its Diagnostics Accelerator program, doubling efforts to accelerate promising...
The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered...
A more robust pipeline of novel targets spanning all clinical trial phases and an ongoing focus on therapeutics driven by the biology of aging offers ...
The Alzheimer's Drug Discovery Foundation (ADDF) has named Dr. Miia Kivipelto as the recipient of the 2021 Melvin R. Goodes Prize for Excellence in...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.